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ABSTRACT
Many people with asthma do not achieve disease
control, despite bronchodilators and inhaled
corticosteroid therapy. People with uncontrolled
asthma are at higher risk of an asthma attack and
death, with mortality rates estimated at 1000 deaths/
year in England and Wales. The recent National Review
of Asthma Deaths (NRAD) report, ‘Why asthma still
kills’, recommended that patients at step 4 or 5 of the
British Thoracic Society/Scottish Intercollegiate
Guidelines Network (BTS/SIGN) guidance must be
referred to a specialist asthma service. This article
reviews the 2014 evidence base for therapy of asthma
patients at BTS/SIGN step 4 of the treatment cascade,
in response to key findings of the NRAD report and
lack of preferred treatment option at this step.
INTRODUCTION
It is estimated that ∼300 million people have
asthma worldwide, with expectations that this
ﬁgure will rise to 400 million by 2025.1 2 The
severity of disease varies and patients with
severe asthma (requiring treatment at steps 4
and 5 of the British thoracic Society/Scottish
Intercollegiate Guidelines Network (BTS/
SIGN)3 guideline)4 often suffer from a worse
quality of life, asthma attacks, hospitalisations
and are at higher risk of death.5 It is thought
that ∼4% of people with asthma suffer from
true severe refractory disease6 and studies
have shown that this subgroup of patients
impart a disproportionate pharmaco-
economic burden, with mean UK annual
treatment costs reaching between £2912 and
£4217 per patient.7
The goal of asthma treatment is to achieve
disease control, which is assessed by clinical
measures and risk (of an asthma attack and
of medication side effects). Poor control is
linked with asthma attacks, which in turn are
associated with poor future control and
healthcare usage.8 9 In the UK, it is estimated
that ∼65% of patients on at least an inhaled
corticosteroid (ICS) with a long-acting β2
adrenergic agonist (LABA) (BTS/SIGN step
3 upwards) remain uncontrolled.10 Potential
factors, other than severity of disease, that
may lead to reduced control include poor
inhaler technique, non-adherence to medica-
tion, exposure to trigger factors and incor-
rect prescribing.
According to the BTS/SIGN guidance,
patients with uncontrolled asthma should
have treatment intensiﬁed by escalating up
the treatment steps until control is achieved
for at least 3 months, at which point ‘step-
ping down’ treatment should be considered
(ﬁgure 1).3 Patients at step 4 are uncon-
trolled, despite receiving at least 800 µg ICS
per day (beclometasone dipropionate (BDP)
or equivalent) plus a LABA (or other con-
troller medication such as theophylline if
LABA is not deemed effective at step 3).
Recommended treatment options at this step
are: increasing the dose of ICS up to
2000 µg/day; adding a leukotriene receptor
antagonist (LTRA); theophylline; β2 adrener-
gic receptor agonist tablet; tiotropium
bromide soft mist inhaler. However, there is
no algorithm to suggest which treatment
should be tried ﬁrst and it is unclear
whether one treatment is more efﬁcacious
than another. Furthermore, it is important to
try and achieve disease control without
resorting to oral steroids which are linked
with osteoporosis, adrenal suppression,
weight gain and diabetes.11
Despite national and international
evidence-based guidelines, the optimal man-
agement strategy in severe asthma is still
unclear due to lack of robust clinical data.
Here, we focus on treatment options at step
4, given the recent National Review of
Asthma Deaths (NRAD) report recommen-
dation for specialist referral12 and lack of
clarity at this step (a review of pharmaco-
logical therapy at each individual treatment
step has been published elsewhere).13
METHOD
A literature review of randomised controlled
clinical trials (RCTs) of each asthma therapy
recommended by the 2014 version of the
BTS/SIGN guidelines at step 4 was
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performed. Evidence included studies used to form the
guideline itself (trials published to August 2012), RCTs
and Cochrane reviews up to April 2016. Embase and
MEDLINE were searched using the primary search
terms ‘asthma’ (title) AND adult AND the therapy being
assessed (title), for example, ‘leukotriene receptor
antagonist’ OR ‘pranlukast’ OR ‘montelukast’ OR ‘zaﬁr-
lukast’. All ICS doses stated are BDP per day or equiva-
lent (µg) (low dose <400 µg, medium 400–800 µg and
high dose ≥800 µg).14
TREATMENT OPTIONS AT STEP 4 OF THE BTS/SIGN
GUIDELINES
Option 1: increasing the dose of ICS
ICS are the cornerstone of asthma therapy and are used
throughout steps 2–5 (ﬁgure 1).3 ICS exert their effects
through binding to glucocorticoid receptors of inﬂam-
matory and structural cells within the airways, initiating
cellular signalling and downregulation of inﬂammatory
gene transcription and inﬂammatory mediator release,
as well as upregulation of anti-inﬂammatory genes. ICS
may also indirectly lead to bronchodilation, either
through reduction in inﬂammatory cell obstruction or
by increasing β2 adrenergic receptor expression.
15
Clinical trials in asthma have shown that ICS reduce
exacerbations and short-acting β2 adrenergic receptor
agonist (SABA) use and also improve FEV1 and asthma
symptoms, across a range of disease severities.16
However, side effects such as adrenal suppression
become more common as the dose increases due to
increased systemic exposure,17 and therefore, it is recom-
mended that treatment is titrated to achieve the lowest
dose possible to maintain disease control.3 It is thought
that most clinical beneﬁts from ICS occur at lower doses
and that few patients beneﬁt from doses above 400–
800 µg, that is, the dose–response curve becomes ﬂat-
tened and side effects occur more frequently at doses
above 800 µg (ﬁgure 2).9 17–21 However, some asthma
patients, including smokers,22 23 do respond clinically to
higher doses of ICS,24 which can be accompanied by a
normal serum cortisol level:25 consequently, no
maximum effective dose can be deﬁned.
Evidence: increasing ICS up to 2000 µg
One option is to increase the dose of ICS from 800 µg
to doses up to and including 2000 µg. As far as we are
aware to date, there are no studies assessing the clinical
Figure 1 British thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) 2014 version of guidelines on the
management of asthma: summary of stepwise management in adults.3 Reproduced from (SIGN 141: British Guideline on the
Management of Asthma, BTS/SIGN, page 72, 2014) with permission from BMJ Publishing Group.
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effectiveness of stepping up ICS in a step 4 patient popu-
lation (already on high-dose ICS (without oral steroids)
+LABA (or other add-on controller)), and the current
guidelines are largely extrapolated from studies in
patients at step 3.3 26 27 It has not been established
whether asthma patients on higher doses of ICS, for
example, 1600 µg, are at lower risk of an asthma attack
compared with those on 800 µg, and so clinical judge-
ment with beneﬁt/risk should guide this initial treat-
ment choice.
Option 2: add-on therapy with LTRA
Leukotrienes are lipid mediators produced by inﬂamma-
tory cells of the airways and are activated during allergic
airway inﬂammation. Pathophysiological effects include
bronchoconstriction, increased microvasculature perme-
ability, mucus secretion and recruitment of eosinophils
into the airway mucosa. Cysteinyl leukotriene (CysLT)
inhibitors (montelukast, zaﬁrlukast and pranlukast) can
improve lung function, symptoms, SABA use, eosinophil
level and exacerbation rate over a range of asthma sever-
ities in adults and children.28 One advantage of adding
another anti-inﬂammatory medication to high-dose ICS
is a potential steroid-sparing effect. LTRA may also
inhibit early and late phase allergen responses, although
the magnitude of effect on airway hyper-responsiveness
(AHR) may be reduced in comparison with ICS.29
Evidence: addition of LTRA compared with placebo/usual
care
Although ICS are used ﬁrst line as a single agent for
asthma,30 31 LTRA do have some beneﬁcial effects when
used with SABA alone27 and the BTS/SIGN guidance
reference seven studies that suggest LTRA may have a
modest effect on lung function, SABA use and asthma
control over placebo.32 A meta-analysis of six studies of
montelukast add-on therapy in mild–moderate asthma
showed improved effectiveness compared with ICS
alone, with regard to symptoms and chances of an
asthma attack.33 However, there are no studies in the
BTS/SIGN guidance that speciﬁcally assess the addition
of LTRA as an add-on maintenance therapy at step 4
compared with placebo or usual care, and guidelines
extrapolate from studies in milder patients.
More recent evidence includes a 6-week double-blind
parallel group trial that assessed 80 mg zaﬁrlukast two
times a day in 368 symptomatic asthma patients on high-
dose ICS (≥1200 µg) plus any usual therapy. The results
showed improved morning/evening PEF, daytime
symptom score, SABA use and exacerbation risk with
LTRA over placebo.34 A second study randomised 37
patients with symptomatic asthma already taking 800–
1200 µg ICS plus a bronchodilator to 225 mg pranlukast
two times a day or normal care over 4 weeks, which
resulted in improved lung function, asthma symptoms,
SABA use and eosinophil levels in the pranlukast arm.35
A similar study assessed 10 mg once daily montelukast as
an add-on therapy to symptomatic asthma patients
taking 400–1600 µg ICS over 16 weeks and showed
increased asthma control and SABA usage compared
with placebo.36 In contrast, two short-term clinical
studies of patients on high-dose ICS (≥1000 µg) showed
no improvement in symptoms, lung function or SABA
use with 10 mg montelukast once daily37 38 Furthermore,
a Cochrane review in adults and children with symptom-
atic asthma concluded that the addition of LTRA had a
modest effect on lung function, but no effect on exacer-
bations requiring steroids.39 Although there is evidence
to suggest that LTRA may be beneﬁcial as an add-on
therapy in step 4 patients, in difﬁcult asthma, LTRA may
only be beneﬁcial in speciﬁc patients.
Evidence: addition of LTRA compared with increasing the
dose of ICS
Several studies have compared LTRA add-on with
increasing the dose of ICS, where addition to 800 µg
ICS seemed to be as efﬁcacious as ICS doubling with
regard to PEF, SABA use, symptom scores, exacerbations,
AHR, eosinophil counts and quality of life.39–42
However, concomitant treatment with bronchodilators
was not permitted in these trials and to the best of our
knowledge, there are no studies speciﬁcally assessing
LTRA as an add-on to high-dose ICS with a LABA com-
pared with doubling/increasing the ICS dose.
Therefore, comparative clinical effectiveness cannot be
determined in a step 4 patient population.
Option 3: add-on therapy with methylxanthines
Theophylline is the most widely used methylxanthine
and slow-release (SR) theophylline is recommended as a
potential add-on therapy at step 4. Theophylline is a
bronchodilator which exerts its effects by inhibition of
phosphodiesterase III and IV, causing smooth muscle
Figure 2 For most patients with asthma airway response
becomes flatter after 1000 µg of inhaled corticosteroid, but
systemic activity (measured by serum cortisol levels) becomes
steeper.17 Reproduced with permission from Professor Brian J
Lipworth.
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relaxation. Theophylline may also have other clinically
relevant properties, including anti-inﬂammatory, immu-
nomodulatory and bronchoprotective effects,43 poten-
tially via mechanisms leading to increased histone
deacetylase.44 SR theophylline was a popular treatment
in the 1980s before concerns around toxicity led to
reduced use: it has a narrow therapeutic index and
serum concentration is linked with clinical beneﬁts and
drug toxicity.43 Side effects include gastric irritation,
vomiting, palpitations and fall in blood pressure.45
Evidence: addition of theophylline compared with placebo/
usual care
Although recommended as an add-on therapy at step 4,
there are no RCTs outlined in the BTS/SIGN evidence
assessing efﬁcacy in this population. A small study of 32
asthma patients on high-dose ICS (1096 µg mean dose)
plus other controller medication, referenced in the
global initiative for asthma (GINA) report, found that
the addition of theophylline improved lung function
and asthma symptoms versus placebo.46 Since the BTS/
SIGN guideline publication, one study randomised 265
patients with asthma to high dose (1000 µg) ICS/LABA
combination plus 200 mg theophylline two times a day
or placebo for 24 weeks and described signiﬁcantly
fewer exacerbations in the theophylline arm (30%) com-
pared with placebo (47%), as well as improved small
airways function (forced expiratory ﬂow (FEF)25–75%)
and reduced sputum eosinophils; however, it is difﬁcult
to assess the impact of this study as patients were initially
treatment naïve and asthma control was variable.47
Evidence: addition of theophylline compared with increasing
the dose of ICS
Two studies outlined in the BTS/SIGN guidance com-
pared theophylline with increasing the dose of ICS.48
The ﬁrst study, which is relevant only to step 3 patients,
showed that 6 weeks of 250 mg theophylline two times a
day plus 400 µg ICS had similar efﬁcacy to 800 µg ICS
alone (lung function, symptoms and rescue medication
use).49 The second 3-month study showed that 800 µg
ICS plus theophylline induced greater improvements in
lung function compared with 1500 µg ICS alone, with
similar improvements in SABA reduction, variability of
PEF and asthma severity. Furthermore, serum cortisol
levels were signiﬁcantly reduced in the 1500 µg ICS
arm.50 Taken together, the addition of theophylline may
have beneﬁts over increasing the dose of ICS and may
also act an effective steroid- sparing agent.
Option 4: add-on therapy with β2 agonist tablets
Sustained-release oral β2 agonist tablets, such as bambu-
terol (a prodrug of terbutaline), act through selective
binding to β2 adrenergic receptors on airway smooth
muscle cells leading to smooth muscle relaxation.51
Although β2 agonist tablets have a 24-hour bronchodila-
tor effect, they are not widely used in a clinical setting
and caution should be taken in patients already on
LABA. Common side effects associated with bambuterol
include tremor, headache, heart palpitations, muscle
cramps and sleep disturbances.52
Evidence: addition of β2 agonist tablets compared with
placebo/usual care or increasing ICS dose
Five clinical trials support the incorporation of oral β2
agonist tablets into the BTS/SIGN guidelines as an
add-on therapy at step 3 and step 4.53 These studies
assessed efﬁcacy compared with inhaled salmeterol or
oral salbutamol. In two studies, salmeterol was more
effective than oral salbutamol with regard to PEF and
need for rescue medication.54 55 However, the remaining
three studies showed that bambuterol was just as efﬁca-
cious as inhaled salmeterol or oral salbutamol in out-
comes, including PEF, FEV1, night-time awakenings,
SABA use and symptoms.56–58 As far as we are aware
there are no studies in step 4 patients assessing the efﬁ-
cacy of oral β2 agonist tablets; (1) as an add-on therapy
to usual care or (2) as an alternative to increasing the
dose of ICS above 800 µg.
Option 5: add-on therapy with tiotropium soft mist solution
Tiotropium bromide is a long-acting (24-hour) muscar-
inic receptor antagonist (LAMA) that inhibits
acetylcholine-mediated constriction of airway smooth
muscle, through antagonism of M3 muscarinic receptors
present on airway smooth muscle cells.59 This broncho-
dilator may also reduce mucus secretion, inﬂammation
(potentially through inﬂammatory cell M3 receptor inter-
actions) and airway remodelling.60–62 Tiotropium has
been used as a maintenance therapy in chronic obstruct-
ive pulmonary disease for over a decade and increasing
evidence has reported clinical effectiveness as an add-on
therapy in asthma.63 Tiotropium is well tolerated64 with
dry mouth being reported as the most common side
effect.59 However, tiotropium may mask underlying
inﬂammatory responses due to a bronchodilator effect
and because no dual ICS/LAMA inhaler currently exists,
the importance of ICS concordance must be emphasised.
Evidence: addition of tiotropium compared with placebo/
usual care
The BTS/SIGN guidelines report two RCTs of tiotro-
pium in asthma, with one comparing tiotropium with
placebo. In this study, 388 asthma patients who were not
controlled on 400–1000 µg ICS±LABA (step 3–4
patients) were randomised to tiotropium, placebo or sal-
meterol. The results showed that tiotropium (5 µg once
daily, soft mist solution) was superior to placebo with
regard to the primary outcome measure PEF, and was
non-inferior to salmeterol (50 µg salmeterol two times a
day) with similar adverse event rates.65 Since the 2014
BTS/SIGN evidence review, three more RCTs in asthma
patients on medium-dose ICS have been published, all
showing an improvement in FEV1 with 5 µg once daily
tiotropium over placebo.66–68 Two RCTs have been
carried out speciﬁcally in step 4 patients: the ﬁrst 8-week
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cross-over study investigated 2 doses of tiotropium (5 µg
and 10 µg once daily) as an add-on therapy in 100
patients with severe asthma uncontrolled on at least
800 µg ICS/LABA, and showed lung function signiﬁ-
cantly improved compared with placebo.69 The second
phase III study compared the effects of 5 µg tiotropium
once daily with placebo in two replicate trials over 1 year
in 912 patients with severe symptomatic asthma who had
experienced at least one severe exacerbation in the pre-
vious year and were taking at least 800 µg ICS plus a
LABA. The peak and trough FEV1 signiﬁcantly improved
and there was a 21% reduction in risk of severe exacer-
bation and 31% reduction in asthma worsenings.70 In
both studies, concomitant theophylline, LTRA and oral
steroids were permitted at stable doses and subanalyses
of the phase III trials showed clinical effectiveness was
independent of allergic/inﬂammatory status and LTRA
use.71 72
Evidence: addition of tiotropium compared with increasing
the dose of ICS
The second study outlined in the guidance was a cross-
over trial which assessed 18 µg once daily tiotropium
(dry powder suspension) compared with doubling low–
medium dose ICS in 210 patients with uncontrolled
asthma. Tiotropium was superior to ICS doubling in
terms of morning PEF, asthma control days, FEV1 pre-
bronchodilator and daily symptom scores and was also
non-inferior to salmeterol in most outcome measures,
with FEV1 favouring tiotropium.
73 However, this study
was not in a step 4 population.
DISCUSSION
Increasing the dose of ICS or add-on therapies: which one
and when?
Current therapeutic options at step 4 are generally based
on dated clinical evidence, involving treatments from the
1960s (β2 agonist tablets), 1970s (theophylline) and 1980s
(LTRAs). ICS are considered the cornerstone of asthma
therapy, however; increasing the dose of ICS is linked with
side effects and a ﬂattened dose–response curve. The 2014
BTS/SIGN guidance warns that theophylline and oral β2
tablets are more likely to cause side effects compared with
other treatments, with omission of β2 tablets from GINA
due to this increased risk.74 LTRA is an effective treatment
in asthma, although it may be most useful in atopic patients
due to mechanism of action. There are few RCTs of tiotro-
pium, but these have shown efﬁcacy at steps 3, 4 and 5 of
the treatment cascade, leading to incorporation into steps
4–5 of the GINA report.74 There are no large head-to-head
trials in uncontrolled patients at this step, and therefore,
treatment decisions should be made according to the evi-
dence we do have and the potential for side effects.
Other potential step 4 treatment options
A low-dose ICS/LABA maintenance and reliever therapy
regime may be more efﬁcacious in reducing asthma
attacks and hospitalisation,75 but may also increase expos-
ure to ICS with unknown long-term safety effects.76
Anti-IgE therapy with the monoclonal antibody omalizu-
mab has been shown to reduce exacerbation frequency
and hospitalisations; however, treatment is expensive and
is only indicated in a select group of patients.77 78 The
recent development of monoclonal antibodies to cytokines
involved in asthma pathophysiology has been encouraging,
with mepoluzimab (an anti-IL-5 antibody which reduces
exacerbations in exacerbation-prone patients with severe
eosinophilic asthma)79 receiving approval in the USA.
However, new monoclonal antibodies mostly target a Th2
high asthma subtype,80 and much like omalizumab before
them, will be limited to use in patients with particular
disease phenotypes and biomarker patterns.
CONCLUSION
The evidence for pharmacological therapy at step 4 of
the 2014 BTS/SIGN asthma management strategy is
limited and current use of asthma therapy at this stage
in the clinic relies heavily upon small clinical trials,
broad licence indications, extrapolation from mild and
moderate disease and observational evidence. Clinical
trials are required to inform which of these treatments
to try ﬁrst and whether or not there are asthma
phenotypes associated with speciﬁc treatment
responses. The new era of biologics is likely to change
how we view asthma severity and the step-up/step-down
paradigm outlined in the 2014 version of the BTS/SIGN
guidance may become less relevant, with stratiﬁed and
personalised medicine becoming more important in the
management of step 4–5 asthma.
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